Danielle Friedman on a Study of Diabetes Among Childhood Cancer Survivors

The Food and Drug Administration granted a traditional approval to Retevmo for adult and pediatric patients 2 years old and older with advanced or metastatic RET fusion-positive thyroid cancer.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

Having social media platforms to share breast cancer experiences changes the narrative for others who may empathize, a survivor and advocate said.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions.

Curing childhood cancer, any kind, is no place to be divided.